Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has provided an update.
Telix Pharmaceuticals Ltd. reported a robust financial performance in Q4 2024, with a revenue of US$142 million, exceeding their FY24 guidance. This growth was primarily driven by strong sales of their prostate cancer imaging product, Illuccix®. The company is advancing its strategic priorities with acquisitions and new product developments, positioning itself for significant expansion in 2025. Notable developments include the progression of clinical trials for prostate and kidney cancer therapies, approvals for imaging products in various markets, and partnerships to enhance their imaging technology.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. is a company operating in the biotech and pharmaceutical industry, primarily focused on developing and commercializing diagnostic and therapeutic radiopharmaceuticals. Their key product, Illuccix®, is used for prostate cancer PET imaging, and the company is expanding its pipeline with various cancer therapies and imaging solutions.
YTD Price Performance: 2.55%
Average Trading Volume: 3,654
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.93B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.
